Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy-Reference-Cited by-同舟云学术

Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy

Published:2023-06 Issue:8 Volume:15 Page:593-610
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Thompson Jake R¹^ORCID,Lai-Kwon Julia²^ORCID,Morton Rachael L¹³^ORCID,Guminski Alexander D¹⁴^ORCID,Gonzalez Maria¹,Atkinson Victoria⁵⁶,Sandhu Shahneen²^ORCID,Brown Michael P⁷⁸⁹^ORCID,Menzies Alexander M¹⁴¹⁰^ORCID,McArthur Grant A²^ORCID,Lo Serigne N¹¹⁰^ORCID,Long Georgina V¹⁴¹⁰¹¹^ORCID,Bartula Iris¹^ORCID

Affiliation:

1. Melanoma Institute of Australia, The University of Sydney, Wollstonecraft, New South Wales, 2065, Australia

2. Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Victoria, 3000, Australia

3. National Health and Medical Research Council Clinical Trials Center, Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, 2050, Australia

4. Royal North Shore & Mater Hospitals, Sydney, New South Wales, 2065, Australia

5. Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia

6. Faculty of Medicine, University of Queensland, Brisbane, Queensland, 4072, Australia

7. Translational Oncology Laboratory, Center for Cancer Biology, SA Pathology & University of South Australia, Adelaide, South Australia, 5001, Australia

8. Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia

9. Adelaide Medical School, University of Adelaide, Adelaide, South Australia, 5005, Australia

10. Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, 2006, Australia

11. Charles Perkins Center, The University of Sydney, Sydney, New South Wales, 2006, Australia

Abstract

Aims: To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab–nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan–Meier method was used to determine median time to first deterioration. Results: Asymptomatic MBM patients treated with ipilimumab–nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement. Conclusion: MBM patients treated with either ipilimumab–nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration: NCT02374242 ( ClinicalTrials.gov )

Funder

Melanoma Institute Australia

Bristol Myers Squibb

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2022-0262

Reference51 articles.

1. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies

2. Prognostic factors for survival in melanoma patients with brain metastases

3. Determinants of Outcome in Melanoma Patients With Cerebral Metastases

4. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features

5. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial;European Journal of Cancer;2024-03